Arrowhead Pharmaceuticals announced that the Chinese National Medical Products Administration (NMPA) has approved its siRNA therapy REDEMPLO (plozasiran) for the reduction of triglyceride levels in adults with familial chylomicronemia syndrome (FCS). The approval, effective January 7 2026, marks the first regulatory clearance for the drug in China and follows the U.S. FDA approval on November 18 2025 and Health Canada’s approval on January 5 2026.
REDEMPLO is administered via a single subcutaneous injection every three months, providing a convenient, home‑based treatment option for patients who previously had limited therapeutic choices. The NMPA clearance is coupled with a $10 million milestone payment from Sanofi, which will market the drug in Greater China under a partnership that began in 2025 when Sanofi acquired the rights to Arrowhead’s cardiometabolic candidates in the region.
The approval expands Arrowhead’s commercial footprint into China, a market with a large population and a growing focus on rare‑disease therapeutics. While FCS remains a rare condition, the Chinese market represents a significant opportunity for a first‑in‑class siRNA therapy, and the milestone payment provides an immediate cash infusion that supports ongoing pipeline development.
Analysts have responded positively to the approval, raising price targets for Arrowhead and highlighting the company’s transition from a clinical‑stage to a commercial‑stage biopharma. The approval is seen as a key driver of future revenue growth, reinforcing confidence in Arrowhead’s platform and its partnership with Sanofi.
Christopher Anzalone, Ph.D., President and CEO of Arrowhead, said the NMPA approval “continues the momentum since the U.S. launch and positions us to bring a life‑changing therapy to patients in China.” He added that the company remains focused on expanding access to REDEMPLO worldwide while advancing its broader RNAi pipeline.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.